Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418532 · ClinicalTrials.gov registry record · Phase 1
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
A Phase 1 study, sponsored by Molecular Partners.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03418532: Clinical Trial Phase 1 study, sponsored by Molecular Partners.
NCT03418532 is a Phase 1 study that was terminated before completion, run by Molecular Partners. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03418532, a Phase 1 study, was terminated before completion, sponsored by Molecular Partners.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced, non squamous NSCLC after tumor progression on osimertinib and on or after the most recent therapy. MP0250 is a multi-DARPin® protein with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.
Primary Outcome
Tumor response will be assessed based on RECIST 1.1 by using CT or MRI
Interventions
- COMBINATION_PRODUCT MP0250 DARPin® drug candidate, Osimertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2020-04-24 |
| Phase | Phase 1 |
Why NCT03418532 stopped before completion
NCT03418532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which MP0250 DARPin® drug candidate, Osimertinib is the first listed.
NCT03418532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03418532 about?
NCT03418532 is a clinical study titled "MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC". The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug candidate in combination with osimertinib orally once daily (o.d.), when administered to patients with EGFR mutated, advanced...
What is the current status of trial NCT03418532?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-03-22. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03418532?
The interventions under investigation include: MP0250 DARPin® drug candidate, Osimertinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03418532?
This trial is sponsored by Molecular Partners, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03418532's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI